AstraZeneca Imfinzi treatment gets FDA priority review
AstraZeneca
11,988.00p
16:40 26/04/24
AstraZeneca said the US Food and Drug Administration had accepted a supplemental Biologics License Application (sBLA) and granted priority review for its Imfinzi treatment of patients with previously untreated extensive-stage small cell lung cancer.
FTSE 100
8,139.83
17:09 26/04/24
FTSE 350
4,470.09
16:59 26/04/24
FTSE All-Share
4,423.59
17:14 26/04/24
Pharmaceuticals & Biotechnology
22,773.26
16:59 26/04/24
The sBLA was based on positive results from a phase III CASPIAN trial published in The Lancet, showing Imfinzi in combination with standard-of-care (SoC) chemotherapy demonstrated a “statistically significant and clinically meaningful” improvement in overall survival vs SoC, the company said on Friday.
The risk of death was reduced by 27%, with median overall survival of 13 months for Imfinzi plus chemotherapy vs. 10.3 months for SoC. Results showed an estimated 33.9% of patients were alive at 18 months following treatment with Imfinzi plus chemotherapy vs. 24.7% of patients receiving SoC.